

Paul E Greenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11812637/publications.pdf>

Version: 2024-02-01

36
papers

6,799
citations

304602

22
h-index

377752

34
g-index

38
all docs

38
docs citations

38
times ranked

8134
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	1.1	7
2	Introduction to the Special Issue of Pharmacoeconomics on Major Depressive Disorders. <i>Pharmacoeconomics</i> , 2021, 39, 617.	1.7	1
3	The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). <i>Pharmacoeconomics</i> , 2021, 39, 653-665.	1.7	302
4	Healthcare resource utilization and costs associated with postpartum depression among commercially insured households. <i>Current Medical Research and Opinion</i> , 2020, 36, 1707-1716.	0.9	20
5	Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. <i>PLoS ONE</i> , 2019, 14, e0223255.	1.1	32
6	Medicaid spending burden among beneficiaries with treatment-resistant depression. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 381-392.	0.6	18
7	Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 24-32.	1.1	97
8	The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010). <i>Journal of Clinical Psychiatry</i> , 2015, 76, 155-162.	1.1	1,321
9	Cost of Illness: An Ongoing Battle Worth Fighting. <i>Pharmacoeconomics</i> , 2014, 32, 1151-1152.	1.7	0
10	Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. <i>American Health and Drug Benefits</i> , 2011, 4, 78-87.	0.5	1
11	Assessing the Relationship Between Compliance With Antidepressant Therapy and Employer Costs Among Employees in the United States. <i>Journal of Occupational and Environmental Medicine</i> , 2010, 52, 115-124.	0.9	14
12	Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. <i>Depression and Anxiety</i> , 2010, 27, 78-89.	2.0	307
13	The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2317-2328.	0.9	21
14	Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. <i>Journal of Medical Economics</i> , 2009, 12, 124-135.	1.0	19
15	Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants. <i>Pharmacoeconomics</i> , 2009, 27, 507-517.	1.7	25
16	Antidepressant treatment patterns and costs among US employees. <i>Journal of Medical Economics</i> , 2009, 12, 36-45.	1.0	3
17	Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. <i>Current Medical Research and Opinion</i> , 2008, 24, 2587-2595.	0.9	23
18	Does generic substitution always make sense?. <i>Journal of Medical Economics</i> , 2008, 11, 547-553.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry, 2007, 64, 543.	13.8	2,032
20	Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001. Clinical Journal of Pain, 2006, 22, 667-676.	0.8	132
21	The economic burden of depression in the US: societal and patient perspectives. Expert Opinion on Pharmacotherapy, 2005, 6, 369-376.	0.9	135
22	Economic Consequences of Not Recognizing Bipolar Disorder Patients. Journal of Clinical Psychiatry, 2003, 64, 1201-1209.	1.1	86
23	The Economic Burden of Depression in the United States. Journal of Clinical Psychiatry, 2003, 64, 1465-1475.	1.1	1,104
24	Economic Burden of Respiratory Infections in an Employed Population. Chest, 2002, 122, 603-611.	0.4	58
25	Direct and indirect costs of asthma to an employer. Journal of Allergy and Clinical Immunology, 2002, 109, 264-270.	1.5	74
26	Identification of a Claims Data "Signature" and Economic Consequences for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2002, 63, 717-726.	1.1	71
27	Cost of depression: current assessment and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2001, 1, 69-76.	0.7	11
28	Depression and Work Productivity: The Comparative Costs of Treatment Versus Nontreatment. Journal of Occupational and Environmental Medicine, 2001, 43, 2-9.	0.9	164
29	Impact of Illness and Its Treatment on Workplace Costs: Regulatory and Measurement Issues. Journal of Occupational and Environmental Medicine, 2001, 43, 56-63.	0.9	26
30	Economic Burden of Pneumonia in an Employed Population. Archives of Internal Medicine, 2001, 161, 2725.	4.3	34
31	Assessing the economic impact of psychiatric disorders: where to begin?. Expert Opinion on Pharmacotherapy, 2001, 2, 641-652.	0.9	0
32	Management of Major Depression in the Workplace. Disease Management and Health Outcomes, 2000, 7, 163-171.	0.3	19
33	Direct and Indirect Costs of Rheumatoid Arthritis to an Employer. Journal of Occupational and Environmental Medicine, 2000, 42, 588-596.	0.9	55
34	Depression In The Workplace: Effects On Short-Term Disability. Health Affairs, 1999, 18, 163-171.	2.5	323
35	Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses. Pharmacoeconomics, 1999, 16, 1-8.	1.7	91
36	Workplace performance effects from chronic depression and its treatment. Journal of Health Economics, 1998, 17, 511-535.	1.3	167